The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Oligodendroglioma


High impact information on Oligodendroglioma


Chemical compound and disease context of Oligodendroglioma


Biological context of Oligodendroglioma


Anatomical context of Oligodendroglioma


Gene context of Oligodendroglioma


Analytical, diagnostic and therapeutic context of Oligodendroglioma


  1. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Dai, C., Celestino, J.C., Okada, Y., Louis, D.N., Fuller, G.N., Holland, E.C. Genes Dev. (2001) [Pubmed]
  2. p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3. Wolf, R.M., Draghi, N., Liang, X., Dai, C., Uhrbom, L., Eklöf, C., Westermark, B., Holland, E.C., Resh, M.D. Genes Dev. (2003) [Pubmed]
  3. Telomerase activity in human brain tumours. Langford, L.A., Piatyszek, M.A., Xu, R., Schold, S.C., Shay, J.W. Lancet (1995) [Pubmed]
  4. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Johannsson, O., Ostermeyer, E.A., Håkansson, S., Friedman, L.S., Johansson, U., Sellberg, G., Brøndum-Nielsen, K., Sele, V., Olsson, H., King, M.C., Borg, A. Am. J. Hum. Genet. (1996) [Pubmed]
  5. Expression of the tumor suppressor gene DCC in human gliomas. Scheck, A.C., Coons, S.W. Cancer Res. (1993) [Pubmed]
  6. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Cairncross, J.G., Ueki, K., Zlatescu, M.C., Lisle, D.K., Finkelstein, D.M., Hammond, R.R., Silver, J.S., Stark, P.C., Macdonald, D.R., Ino, Y., Ramsay, D.A., Louis, D.N. J. Natl. Cancer Inst. (1998) [Pubmed]
  7. OLIG2 as a specific marker of oligodendroglial tumour cells. Marie, Y., Sanson, M., Mokhtari, K., Leuraud, P., Kujas, M., Delattre, J.Y., Poirier, J., Zalc, B., Hoang-Xuan, K. Lancet (2001) [Pubmed]
  8. BDNF modulates GABAA receptors microtransplanted from the human epileptic brain to Xenopus oocytes. Palma, E., Torchia, G., Limatola, C., Trettel, F., Arcella, A., Cantore, G., Di Gennaro, G., Manfredi, M., Esposito, V., Quarato, P.P., Miledi, R., Eusebi, F. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  9. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Lu, Q.R., Park, J.K., Noll, E., Chan, J.A., Alberta, J., Yuk, D., Alzamora, M.G., Louis, D.N., Stiles, C.D., Rowitch, D.H., Black, P.M. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  10. The human myelin basic protein gene is included within a 179-kilobase transcription unit: expression in the immune and central nervous systems. Pribyl, T.M., Campagnoni, C.W., Kampf, K., Kashima, T., Handley, V.W., McMahon, J., Campagnoni, A.T. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  11. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. Hoang-Xuan, K., Capelle, L., Kujas, M., Taillibert, S., Duffau, H., Lejeune, J., Polivka, M., Crinière, E., Marie, Y., Mokhtari, K., Carpentier, A.F., Laigle, F., Simon, J.M., Cornu, P., Broët, P., Sanson, M., Delattre, J.Y. J. Clin. Oncol. (2004) [Pubmed]
  12. Glial cell-specific differences in repair of O6-methylguanine. LeDoux, S.P., Williams, B.A., Hollensworth, B.S., Shen, C., Thomale, J., Rajewsky, M.F., Brent, T.P., Wilson, G.L. Cancer Res. (1996) [Pubmed]
  13. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. Buckner, J.C., Gesme, D., O'Fallon, J.R., Hammack, J.E., Stafford, S., Brown, P.D., Hawkins, R., Scheithauer, B.W., Erickson, B.J., Levitt, R., Shaw, E.G., Jenkins, R. J. Clin. Oncol. (2003) [Pubmed]
  14. Selective induction by N-nitrosoethylurea of oligodendrogliomas in fetal forebrain transplants. Burger, P.C., Shibata, T., Aguzzi, A., Kleihues, P. Cancer Res. (1988) [Pubmed]
  15. The identification and characterization of oligodendrocyte thromboxane A2 receptors. Blackman, S.C., Dawson, G., Antonakis, K., Le Breton, G.C. J. Biol. Chem. (1998) [Pubmed]
  16. Homozygous deletions of the CDKN2C/p18INK4C gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas. Pohl, U., Cairncross, J.G., Louis, D.N. Brain Pathol. (1999) [Pubmed]
  17. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. Shaw, E., Arusell, R., Scheithauer, B., O'Fallon, J., O'Neill, B., Dinapoli, R., Nelson, D., Earle, J., Jones, C., Cascino, T., Nichols, D., Ivnik, R., Hellman, R., Curran, W., Abrams, R. J. Clin. Oncol. (2002) [Pubmed]
  18. The contribution of genetic and epigenetic mechanisms to gene silencing in oligodendrogliomas. Hong, C., Bollen, A.W., Costello, J.F. Cancer Res. (2003) [Pubmed]
  19. Somatic mutations of the von Hippel-Lindau tumor suppressor gene and loss of heterozygosity on chromosome 3p in human glial tumors. Kanno, H., Shuin, T., Kondo, K., Yamamoto, I., Ito, S., Shinonaga, M., Yoshida, M., Yao, M. Cancer Res. (1997) [Pubmed]
  20. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Zlatescu, M.C., TehraniYazdi, A., Sasaki, H., Megyesi, J.F., Betensky, R.A., Louis, D.N., Cairncross, J.G. Cancer Res. (2001) [Pubmed]
  21. Unexpected expression of intermediate filament protein genes in human oligodendroglioma cell lines. Kashima, T., Vinters, H.V., Campagnoni, A.T. J. Neuropathol. Exp. Neurol. (1995) [Pubmed]
  22. Molecular cloning of IL-2R alpha, IL-2R beta, and IL-2R gamma cDNAs from a human oligodendroglioma cell line: presence of IL-2R mRNAs in the human central nervous system. Otero, G.C., Merrill, J.E. Glia (1995) [Pubmed]
  23. An immunochemical investigation of 2':3'-cyclic nucleotide 3'-phosphodiesterase (CNP) in bovine cerebrum and human oligodendroglioma. Sheedlo, H.J., Yaghmai, F., Wolfe, L., Sprinkle, T.J. J. Neurosci. Res. (1985) [Pubmed]
  24. Heme oxygenase (HO)-1 expressing macrophages/microglial cells accumulate during oligodendroglioma progression. Deininger, M.H., Meyermann, R., Trautmann, K., Duffner, F., Grote, E.H., Wickboldt, J., Schluesener, H.J. Brain Res. (2000) [Pubmed]
  25. Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. Watanabe, T., Yokoo, H., Yokoo, M., Yonekawa, Y., Kleihues, P., Ohgaki, H. J. Neuropathol. Exp. Neurol. (2001) [Pubmed]
  26. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. Fallon, K.B., Palmer, C.A., Roth, K.A., Nabors, L.B., Wang, W., Carpenter, M., Banerjee, R., Forsyth, P., Rich, K., Perry, A. J. Neuropathol. Exp. Neurol. (2004) [Pubmed]
  27. Expression of the oligodendroglial lineage-associated markers Olig1 and Olig2 in different types of human gliomas. Ohnishi, A., Sawa, H., Tsuda, M., Sawamura, Y., Itoh, T., Iwasaki, Y., Nagashima, K. J. Neuropathol. Exp. Neurol. (2003) [Pubmed]
  28. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. Ligon, K.L., Alberta, J.A., Kho, A.T., Weiss, J., Kwaan, M.R., Nutt, C.L., Louis, D.N., Stiles, C.D., Rowitch, D.H. J. Neuropathol. Exp. Neurol. (2004) [Pubmed]
  29. Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas. Idbaih, A., Crinière, E., Marie, Y., Rousseau, A., Mokhtari, K., Kujas, M., El Houfi, Y., Carpentier, C., Paris, S., Boisselier, B., Laigle-Donadey, F., Thillet, J., Sanson, M., Hoang-Xuan, K., Delattre, J.Y. Neuro-oncology (2008) [Pubmed]
  30. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. Chinot, O.L., Honore, S., Dufour, H., Barrie, M., Figarella-Branger, D., Muracciole, X., Braguer, D., Martin, P.M., Grisoli, F. J. Clin. Oncol. (2001) [Pubmed]
  31. Characterization of insulin-like growth factor 1 in human primary brain tumors. Sandberg-Nordqvist, A.C., Ståhlbom, P.A., Reinecke, M., Collins, V.P., von Holst, H., Sara, V. Cancer Res. (1993) [Pubmed]
  32. Epidermal growth factor receptor expression in oligodendroglial tumors. Reifenberger, J., Reifenberger, G., Ichimura, K., Schmidt, E.E., Wechsler, W., Collins, V.P. Am. J. Pathol. (1996) [Pubmed]
  33. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Nutt, C.L., Betensky, R.A., Brower, M.A., Batchelor, T.T., Louis, D.N., Stemmer-Rachamimov, A.O. Clin. Cancer Res. (2005) [Pubmed]
  34. Detection of chromosomal changes by interphase cytogenetics in biopsies of recurrent astrocytomas and oligodendrogliomas. Rosso, S.M., van Dekken, H., Krishnadath, K.K., Alers, J.C., Kros, J.M. J. Neuropathol. Exp. Neurol. (1997) [Pubmed]
WikiGenes - Universities